FiercePharma reports that an influential analyst for the pharma sector has just downgraded Merck shares. See the post here. Tim Anderson of Sanford Bernstein recently cited a number of reasons for his negative stance with regards to Merck ranging from the problems with Singulair and Gardasil to problems with Merck's pipeline.
It sure is tough being a Big Pharma firm these days.....
Subscribe to:
Post Comments (Atom)
.jpg)
No comments:
Post a Comment